AnaptysBio, Inc. (NASDAQ:ANAB) had its target price lifted by equities research analysts at Credit Suisse Group from $38.00 to $85.00 in a report issued on Tuesday. Credit Suisse Group’s target price would suggest a potential upside of 20.72% from the stock’s current price.
Other research analysts have also recently issued research reports about the stock. JMP Securities upped their target price on shares of AnaptysBio from $45.00 to $82.00 and gave the company an “outperform” rating in a research report on Tuesday. Zacks Investment Research raised shares of AnaptysBio from a “hold” rating to a “buy” rating and set a $36.00 target price on the stock in a research report on Wednesday, September 13th. Royal Bank Of Canada assumed coverage on shares of AnaptysBio in a research report on Thursday, September 14th. They issued an “outperform” rating and a $40.00 target price on the stock. Stifel Nicolaus reaffirmed a “buy” rating and issued a $35.00 target price on shares of AnaptysBio in a research report on Tuesday, September 12th. Finally, Robert W. Baird assumed coverage on shares of AnaptysBio in a research report on Monday, July 10th. They issued an “outperform” rating and a $36.00 target price on the stock. Seven research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average price target of $54.43.
Shares of AnaptysBio (NASDAQ:ANAB) traded up 101.17% during midday trading on Tuesday, hitting $70.41. 5,823,448 shares of the stock traded hands. The company’s 50 day moving average price is $34.23 and its 200-day moving average price is $34.23. The stock’s market cap is $1.43 billion. AnaptysBio has a 12-month low of $15.17 and a 12-month high of $70.48.
AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Thursday, August 10th. The biotechnology company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.42) by $0.29. The company had revenue of $7.00 million during the quarter, compared to analyst estimates of $3.45 million. On average, equities research analysts expect that AnaptysBio will post ($1.98) EPS for the current year.
COPYRIGHT VIOLATION WARNING: “AnaptysBio, Inc. (ANAB) PT Raised to $85.00” was reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.themarketsdaily.com/2017/10/10/anaptysbio-inc-anab-pt-raised-to-85-00.html.
In other AnaptysBio news, major shareholder Holdings A/S Novo sold 70,706 shares of the business’s stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $23.31, for a total transaction of $1,648,156.86. Following the sale, the insider now directly owns 3,009,949 shares in the company, valued at $70,161,911.19. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the business’s stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $24.35, for a total transaction of $901,924.00. The disclosure for this sale can be found here. Insiders have sold 1,133,940 shares of company stock worth $24,223,316 over the last quarter.
A number of large investors have recently modified their holdings of ANAB. Bank of New York Mellon Corp purchased a new stake in AnaptysBio during the first quarter worth about $373,000. JPMorgan Chase & Co. purchased a new stake in AnaptysBio during the first quarter worth about $3,851,000. TIAA CREF Investment Management LLC purchased a new stake in AnaptysBio during the first quarter worth about $227,000. MARSHALL WACE ASIA Ltd purchased a new stake in AnaptysBio during the first quarter worth about $6,924,000. Finally, Marshall Wace North America L.P. purchased a new stake in AnaptysBio during the first quarter worth about $6,924,000. Institutional investors own 71.35% of the company’s stock.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.